Safety and efficacy of initiating highly active anti retroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 3, 2008, Pages 276-281

  Black, Vivian ^a   Hoffman, Risa M ^b,d   Sugar, Catherine A ^c   Menon, Priya ^a   Venter, Francois ^a   Currier, Judith S ^b   Rees, Helen ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

High active antiretroviral therapy (HAART); HIV AIDS; Pregnancy; Prevention of mother to child transmission (PMTCT)

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; FOLLOW UP; GESTATIONAL AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; OUTPATIENT DEPARTMENT; PREGNANCY; PREGNANT WOMAN; PRENATAL CARE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SOUTH AFRICA; TUBERCULOSIS; VERTICAL TRANSMISSION; VIROTHERAPY; VIRUS LOAD; VIRUS TRANSMISSION; ADOLESCENT; DISEASE TRANSMISSION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; NEWBORN; PREGNANCY COMPLICATION;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 58149160365     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318189a769     Document Type: Article

References (24)

1. Department of Health RoSA. National HIV and Syphilis Prevalence Survey South Africa 2005. Available at: http://www.hivan.org.za/admin/ documents/ancnivsummary.pdf Accessed May 8, 2008.
2. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal singledose nevirapine compared with zidovudine for prevention of motherto-child transmission of HIV-I in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
3. Barron P, Day C, Monticelli F. District Health Barometer 2005-2006. Available at: http://www.hst.org.za/uploads/files/secB-gp.pdf Accessed June 18, 2008.
4. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-I in Abidjan, Cote d'Ivoire: a randomised trial. Lancet. 1999;353:781-785.
5. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-I in Thailand. N Engl J Med. 2004;351:217-228.
6. HIV WGoM-t-CTo. Rates of mother-to-child transmission of HIV-I in Africa, America and Europe: results from 13 perinatal studies. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:506-510.
7. Bradshaw D, Chopra M, Kerber K, et al. Every death counts: use of mortality audit data for decision making to save the lives of mothers, babies, and children in South Africa. Lancet. 2008;371:1294-1304.
8. Barreto RL, Soares JM. Jr, Simoes RS, et al. Effects of chronic stavudine exposure on liver, pancreas and kidneys of pregnant rats and their fetuses: morphological and biochemical aspects. Eur J Obstet Gynecol Reprod Biol. 2006;128(l-2):50-53.
9. Wade NA, Unadkat JD, Huang S, et al. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J Infect Dis. 2004;190: 2167-2174.
10. Geddes R, Knight S, Moosa MY, et al. A high incidence of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic acidosis in HIV-infected patients in a South African context. S Afr Med J. 2006; 96:722-724.
11. Currier JS. Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women. Clin Infect Dis. 2007;45:261-262.
12. Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis. 2007;45: 254-260.
13. Luzzati R, Del Bravo P, Di Perri G, et al. Riboflavine and severe lactic acidosis. Lancet. 1999;353:901-902.
14. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-I positive women taking antiretroviral medication. Sex Transm Infect. 2002;78(l):58-59.
15. Mandelbrot L, Kermarrec N, Marcollet A, et al. Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. AIDS. 2003;17:272-273.
16. (BMS) B-MSC. Important Change in Sustiva (efavirenz) [package insert]-Change from Pregnancy Category C to D. FDA Medwatch. Available at: http://www.fda.gov/medwaTCH/safety/ 2005/Sustiva- DHCPletter-061005.pdf Accessed May 8, 2008.
17. Cassol E, Page T, Mosam A, et al. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8. J Infect Dis. 2005;191:324-332.
18. Akileswaran C, Lurie MN, Flanigan TP, et al. Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis. 2005;41: 376-385.
19. Ureland K Cardiorespiratory Physiology of Pregnancy. Vol 3. Baltimore, MD: Harper and Row; 1979.
20. Assali N Pathophysiology of Gestation, Vol 1: Maternal Disorders. New York: Academic Press; 1972.
21. Tai JH, Udoji MA, Barkanic G, et al. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis. 2007;196:1044-1052.
22. Martinson NA, Ekouevi DK, Dabis F, et al. Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2007;45:206-209.
23. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-I-infected women and prevention of perinatal HIV-I transmission. J Acquir Immune Defic Syndr. 2002;29:484-494.
24. Centers for Disease Control. Achievements in public health. Reduction in perinatal transmission of HIV infection-United States, 1985-2005. MMWR Morb Mortal Wkly Rep. 2006;55:592-597.